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Abstract: The application of anthracyclines in anticancer therapy may result in accidental 
extravasation injury and can be a serious complication of their use. Tissue necrosis with skin 
ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during 
intravenous administration. Until recently, there has been no effective treatment against the 
devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to 
the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline 
extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in 
preventing skin necrosis and ulceration. This review focuses on the development and management 
of dexrazoxane in anthracycline extravasation injuries.
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Introduction
The extravasation of vesicant cancer chemotherapeutic agents, especially anthracyclines, 
remains one of the most distressing complications that hematologists and oncologists 
face in cytostatic, intravenous (iv) chemotherapy. Tissue necrosis with skin ulceration 
is a possible outcome in the inadvertent extravasation of several cytotoxic drugs during 
iv administration. The management of this complication remains an important challenge 
in cancer patients.1 Several methods including hyperbaric oxygen therapy and dif-
ferent antidotes have been proposed in this setting with the aim to prevent or reduce 
tissue necrosis.2 In July 2006 the EMEA approved dexrazoxane (Savene®; TopoTarget 
A/S, Copenhagen, Denmark) and in September 2007 the FDA approved dexrazoxane 
(Totect®; TopoTarget A/S, Copenhagen, Denmark) for the treatment of extravasation 
of intranvenous (iv) anthracycline chemotherapy.3,4 In this paper the management of 
anthracycline extravasation with dexrazoxane will be reviewed.
Incidence of extravasation
The estimated incidence of extravasation injuries ranges from 0.1% to 6%.5,6 In a 
series from the MD Anderson Cancer center the incidence of extravasation ranged 
between 0.1% and 1.0 % (44 cases of 40,000 to 60,000 treatments). In these 44 patients, 
12 patients suffered from a doxorubicin extravasation.
The implantation of venous access ports is intended to create a safe access to the 
venous system and thus avoid the likelihood of extravasation.7,8 However, the use of 
central venous access devices may reduce but does not eliminate the risk of extrava-
sation.9–12 Although much safer than peripheral vein access, extravasation may also Therapeutics and Clinical Risk Management 2009:5 362
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occur when using central venous port catheters with severe 
complications, eg, mediastinitis.7
Classification of vesicant, irritant 
or non-vesicant chemotherapeutic 
agents
Based on their potential for causing local tissue injury, 
chemotherapeutic agents are classified as vesicant, irritant 
or non-vesicant.13–17
Vesicant drugs have the capability to induce the formation 
of blisters and/or cause tissue destruction (eg, anthracyclines, 
amsacrin cisplatin, epirubicin, idarubicin, mitomycin c, 
mitoxantrone, paclitaxel, vinca alkaloids).
Irritant drugs can cause pain at the injection site or along 
the vein with or without an inflammatory reaction. Some of 
these agents have the potential to cause soft tissue ulcers 
only if a large amount cytotoxic agent solution is extrava-
sated (eg, carboplatin, bendamustine, dacarbacin, docetaxel, 
etoposide, gemcitabine, ifosfamide, melphalan, topotecan).
Non-vesicant drugs, if extravasated, rarely produce acute 
reaction of tissue necrosis (eg, asparaginase, bleomycin, 
cyclophosphamide, cytarabine, fluorouracil, folinic acid, 
irinotecan, methotrexate, rituximab, thiopeta).
Clinical course of extravasation 
of vesicant drugs and of anthracyclines
An anthracycline extravasation is characterized by swelling 
and redness and is often very painful. Over a period of days 
or weeks this may progress to tissue necrosis producing 
tissue sloughing and ulceration with large wounds requiring 
surgical debridement and/or skin grafts.18–20
Anthracyclines can persist in tissues for weeks or even 
months after extravasation. Furthermore, the local area of 
extravasation is at high risk of infection, because of both the 
local necrosis and in general by the impaired immunological 
state of most patients receiving this kind of treatment.13,21 The 
progression rate to ulceration of significant anthracycline 
extravasation ranges between 25% and 50%.22,23
The tissue damage may progress over days and weeks, 
causing pain and increasing the risk of infection, joint 
destruction, lesions of nerves and permanent dysfunctional 
and cosmetic changes in the involved area. Even the need for 
amputating the extremity is possible in case of anthracycline 
extravasation.24–26
Dexrazoxane
The approval of dexrazoxane was based on efficacy 
studies conducted in Europe to evaluate dexrazoxane as a 
post-extravasation treatment.28,29 Also several case reports 
about the successful treatment with dexrazoxane had been 
published.8,30 In summary, in each study the observed treatment 
frequency and severities of tissue damage appeared to be 
reduced significantly by dexrazoxane infusions given after 
anthracycline extravasation.
Chemistry of dexrazoxane
Dexrazoxane (ICRF-187) can be considered to be a neutral 
pro-drug analogue to the tetra-acid metal chelator EDTA. 
Chemically, dexrazoxane is 2,6-piperazinedione,4,4’-(1-
methyl-1,2-ethanediyl) bis-,(S)- or (S)-(+)-1,2-bis(3,5-
dioxopiperazin-1-yl)propane. Figure 1 shows the chemical 
structure.
The molecular formula is C11H16N4O4; the molecular 
weight is 268.3. Dexrazoxane is a white to off-white powder, 
with a melting point of 194 ± 3°C. It is soluble in dioxane 
and 0.1 N HCl, sparingly soluble in water, tetrahydrofuran, 
citrate buffer at pH 4.0, phosphate buffer at pH 7.0, and 
borate-potassium chloride sodium hydroxide buffer at pH 
9.0. The acid dissociation constants, pKa, are 2.5 (for the 
tertiary piperazine nitrogen) and 9.7 (for the nitrogen imide). 
The log P is -2.135.
Mechanism of action
The mechanism by which dexrazoxane diminishes tissue 
damage resulting from the extravasation of anthracycline 
drugs is unknown.
However, two ways of action are discussed:
1.  Reduction of oxidative stress due to complexes of metal 
ions and anthracyclines by chelating metal ions
2.  Blockade of  topoisomerase II poisons by catalytic inhibition 
of topoisomerase II
N
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Figure 1 Chemical structure of dexrazoxane.Therapeutics and Clinical Risk Management 2009:5 363
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Dexrazoxane is able to penetrate the cell membrane and is 
degraded to ADR-925 by intracellular hydrolysis. ADR-925 
is a strong chelating agent, which is able to form stabile 
complexes with iron, copper and other metal ions and also 
able to remove metal ions from complexes of doxorubicin 
and these ions.31,32 If oxidative stress caused by metal ions is 
assumed to cause tissue damage in anthracycline extravasa-
tion, chelating agents such as ADR-925 or EDTA should be 
able to reduce the level of damage after extravasation. In mice 
this effect could not be detected in systemic and intralesional 
use of EDTA or ADR-925.33
It has been shown that dexrazoxane reversibly inhibits 
topoisomerase II.34 However, it is difficult to identify a 
mechanism by which this could occur, as these tissues are 
not rapidly proliferating and contain only low levels of 
topoisomerase II. This is also underlined by the fact that 
two other non-chelating catalytic agents, merbarone and 
aclarubicin, also inhibitors of topoisomerase II, failed to 
prevent anthracycline-induced extravasation injuries in 
animals.27,33
Pharmacokinetics/pharmacodynamics
The pharmacokinetics of dexrazoxane initially have been 
studied in patients with advanced cancer having normal 
renal and hepatic function. Generally, the pharmacokinetics 
of dexrazoxane can be adequately described by an open 
two-compartment model with first-order elimination. 
Dexrazoxane has been administered as a 15-minute infu-
sion over a dose range of 60 to 900 mg/m2 with 60 mg/m2 of 
doxorubicin, and at a fixed dose of 500 mg/m2 with 50 mg/m2 
doxorubicin.28,35,36
The disposition kinetics of dexrazoxane are dose-
independent, as shown by a linear relationship between 
the area under plasma concentration-time curves and 
administered doses ranging from 60 to 900 mg/m2. The 
important pharmacokinetic parameters of dexrazoxane are 
listed in Table 1.
Qualitative metabolism studies with dexrazoxane have 
confirmed the presence of unchanged drug, a diacid-diamide 
cleavage product, and two monoacid-monoamide ring prod-
ucts in the urine of animals and man.
The metabolite levels were not measured in the pharma-
cokinetic studies.
Urinary excretion plays an important role in the elimination 
of dexrazoxane. In vitro studies have shown that dexrazoxane 
is not bound to plasma proteins.
Accumulation of dexrazoxane has been the main 
point of interest in study TT04 which followed the first 
two multicenter studies (TT01 and TT02) examining the 
efficacy of dexrazoxane in preventing ulcerations. Levels of 
dexrazoxane have been measured during the 3-day scheme 
of application (1000, 1000 and 500 mg/m²) in patients 
suffering from an anthracycline extravasation. Six patients 
could be enrolled in this pharmacokinetics study. An 
accumulation of dexrazoxane could not be found any of 
these patients.
Drug interactions
There were no significant changes in the pharmacokinetics 
of doxorubicin (50 mg/m2) and its predominant metabolite, 
doxorubicinol, in the presence of dexrazoxane (500 mg/m2) 
in a crossover study in cancer patients.35
“Drug history” in regard 
to extravasation
In 2000 the first report on experimental subcutaneous (sc) 
injuries in mice caused by anthracycline successfully treated 
with dexrazoxane was published by Langer et al.34 At this 
time dexrazoxane was registered only as a cardio-protective 
agent (Zinecard®; Pfizer; Cardioxane®; Novartis) against 
anthracycline-induced cardiotoxicity. In this paper, the 
authors discussed the topoisomerase II interaction as the 
inhibitory mechanism for its efficacy.
Also in 2000 the same authors reported two clinical cases 
of successful anthracycline extravasation treatment with 
dexrazoxane. In one case the patient experienced extravasa-
tion of epirubicin into the forearm; in the other case a total of 
149 mg of doxorubicin infiltrated subcutaneously in the chest 
wall due to port needle displacement. Both patients received 
treatment with dexrazoxane 1000 mg/m² administered 
intravenously on day 1 and 2, and 500 mg/m² on day 3. As a 
result, no surgical intervention was required and at 3 months 
of follow up neither of the patients showed sequelae.37 
Table 1 Summary of mean (% coefficient of variation) dexrazoxane 
pharmacokinetic parameters at a dosage ratio of 10:1 of dexrazoxane:
doxorubin
Dose doxorubicin (mg/m²) 50 60
Dose dexrazoxane (mg/m²) 500 600
Number of subjects 10 5
elimination half-life (h) 2.5 (16) 2.1 (29)
Plasma clearance (L/h/m²) 7.88 (18) 6.25 (31)
Renal clearance (L/h/m²) 3.35 (36) –
volume of distribution (L/m²)a 22.4 (22) 22.0 (55)
aSteady stage volume of distribution.Therapeutics and Clinical Risk Management 2009:5 364
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As a consequence of these findings a prospective clinical 
multi-center study was initiated.
Non-clinical studies with dexrazoxane
In an earlier series of preclinical studies, it was demonstrated 
that dexrazoxane administration soon after sc injection 
of doxorubicin, daunorubicin or idarubicin significantly 
reduces or prevents the formation of cutaneous lesions in 
mice.3,33,34,38
Clinical studies with dexrazoxane 
(TT01/TT02)
The results of two prospective multi-center. single-arm, 
open-label phase II/III clinical trials (TT01 and TT02) to 
evaluate the efficacy of iv dexrazoxane in the prevention of 
severe anthracycline-induced extravastion injuries have been 
published recently.28
The primary endpoints of these two studies were preventing 
patients from undergoing surgical debridement of the 
affected area as well as preventing development of sequelae. 
Secondary endpoints were prevention of postponement of 
the scheduled cancer treatment and evaluation of tolerability 
and safety of dexrazoxane. To assure “real extravasation” 
of anthracyclines the diagnosis of extravasation had to be 
confirmed by positive fluorescence microscopy in at least one 
biopsy of the affected region. Local cooling of the extrava-
sation site was permitted, but not within 15 minutes before 
the application of dexrazoxane, whereas local treatment with 
dimethylsulfoxide (DMSO) or steroids were not allowed.
The 3-day treatment schedule with dexrazoxane consisted 
of a daily dose of 1000 mg/m² on day 1–2 and 500 mg/m² on 
day 3. The infusion had to be given in the opposite arm of the 
extravasation site and was administered as soon as possible 
and no longer than 6 hours after the extravasation accident.
In both studies, 54 patients, mainly women with breast 
cancers, were included in the final analysis. The results of the 
combined studies showed that in 53 of 54 (98.2%) included 
patients, treatment with dexrazoxane prevented necrosis 
requiring surgical intervention. Only one patient (1.8 %) 
had to undergo surgical debridement. Thirty-eight patients 
(71.0%) were able to continue their scheduled chemotherapy 
without delay. In addition to bone marrow suppression, as 
expected from the fact that the extravasation happened during 
a chemotherapy course, temporarily infusion site pain (19%), 
mild sensory disturbance (17%), nausea, vomiting, diarrhea, 
stomatitis and transient alteration in liver enzymes have 
been observed. All adverse events were rapidly reversible. 
Although difficult to access due to parallel chemotherapy 
application, the safety profile of dexrazoxane appears to be 
good. In Table 2 the sequelae of the combined studies at the 
3-month follow-up are shown.
There have also been single cases of intrapleural extrava-
sation of epirubicin caused by catheter tip misplacement that 
have been successfully treated with dexrazoxane.11
Dosage and administration 
of dexrazoxane
Dexrazoxane should be given once daily for three consecutive 
days. The first infusion has to be initiated as soon as possible 
and within the first six hours after extravasation.28
The recommended doses are as suggested by Mouridsen:28
day 1  1000 mg/m²  2000 mg max. recommended dose
day 2  1000 mg/m²  2000 mg max. recommended dose
day 3  500 mg/m²  1000 mg max. recommended dose
A dose reduction by 50% of dexrazoxane is necessary in 
patients with creatinine clearance values  40 mL/min.
Dexrazoxane should be administered as an iv infusion 
over 1 to 2 hours in a large caliber vein in an extremity/area 
other than the one affected by the extravasation.39 Cooling 
procedures such as dry cold packs should be removed from 
the area at least 15 minutes before the infusion of dexra-
zoxane in order to allow sufficient blood flow in the area of 
extravasation. Treatment on day 2 and day 3 should start at 
the same time (± 3 hours) as on the first day.
Precautions
When administered to patients receiving anthracycline-
containing cytotoxic therapy, additive cytotoxicity may 
occur, as dexrazoxane is a cytotoxic drug itself. Therefore, 
hematological monitoring should be performed. Reversible 
elevations of liver enzymes may occur with dexrazoxane.
DMSO should not be used in patients who are receiving 
dexrazoxane to treat anthracycline-induced extravasation40 
(see below). Women who have the potential to become 
Table 2 Sequelae at 3-month follow-up in studies TT01 and TT0228,47
Sequelae TT01 / TT02 (N = 54)
None 39 (72.2 %)
At least one 15 (27.8 %)
Sensory disturbances 9 (16.7 %)
Skin atrophy 5 (9.3 %)
Pain 10 (18.5 %)
Disfigurement 1 (1.9 %)
Limitation of movement 1 (1.9 %)Therapeutics and Clinical Risk Management 2009:5 365
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pregnant should be advised that dexrazoxane might cause 
fetal harm.
Dexrazoxane and DMSO
Before the introduction of dexrazoxane the standard 
treatment of anthracycline extravasation was the application 
of DMSO with or without cortisone.41,42 Therefore the 
question was raised if the addition of  DMSO to dexrazoxane 
in extravasation injury would be beneficial. Langer et al 
compared the efficacy of topical DMSO and systemic 
dexrazoxane as monotherapy as well as in combina-
tion against anthracycline-induced ulceration in mice.40 
The addition of topical DMSO to the systemic dexrazoxane 
treatment resulted in the occurrence of wounds in 6 of 
9 (66%) of the mice compared to none for dexrazoxane 
alone. The authors concluded that the addition of topical 
DMSO to iv dexrazoxane treatment resulted in decreased 
efficacy. Although the study was conducted in animals, the 
results do not support the use of DMSO in combination with 
dexrazoxane.
Dexrazoxane and liposomal 
anthracyclines
In the study by Mouridsen only one patient received 
liposomal anthracycline, who did respond but not as well as 
the other patients.28 From this single case it is impossible to 
draw any firm conclusions; however it is conceivable that 
dexrazoxane may not be as effective in these patients, as the 
initial injury is masked by the liposomal envelope surrounding 
the anthracycline.
In case reports about extravasations of liposomal anthra-
cyclines, their ulcerative potency is described as being much 
weaker than that of non-liposomal anthracyclines. The 
actions taken after extravasation did not include the use of 
dexrazoxane.43,44
Nevertheless, the ulcerative potential of liposomal anthra-
cyclines might be a matter of the amount of extravasated 
agent, as small amounts did not cause ulcers (irritant) but 
larger quantities of extravasated liposomal cytotoxic drugs 
caused severe tissue defects (vesicant).45
As a possible cause of this reduced harmfulness, an 
evacuation of liposomal drugs via the lymphatic system has 
been proved in mice models.46
Conclusions
Dexrazoxane is an important development in the management 
of anthracycline extravasation. In case of a positively identified 
anthracycline extravasation it should be available within 6 hours 
and administered in the licensed 3-day course. However, the 
introduction of this new antidote needs to be audited for its 
efficacy in actual practice and further research work should 
be performed to better refine and develop its use.
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